药品注册申请号:018081
申请类型:NDA (新药申请)
申请人:ABBVIE
申请人全名:ABBVIE INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 DEPAKENE VALPROIC ACID CAPSULE;ORAL 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No None 1978/02/28 Approved Prior to Jan 1, 1982 Discontinued
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2020/05/19 SUPPL-71(补充) Approval Labeling STANDARD
2019/11/22 SUPPL-70(补充) Approval Labeling STANDARD
2019/02/21 SUPPL-69(补充) Approval Labeling STANDARD
2018/03/06 SUPPL-68(补充) Approval Labeling STANDARD
2017/10/05 SUPPL-67(补充) Approval Labeling STANDARD
2017/03/06 SUPPL-66(补充) Approval Labeling STANDARD
2016/11/02 SUPPL-65(补充) Approval Labeling STANDARD
2016/02/18 SUPPL-64(补充) Approval Labeling STANDARD
2015/09/23 SUPPL-63(补充) Approval Labeling STANDARD
2015/03/13 SUPPL-62(补充) Approval Labeling STANDARD
2015/01/07 SUPPL-59(补充) Approval Labeling STANDARD
2014/11/20 SUPPL-58(补充) Approval Labeling STANDARD
2014/08/20 SUPPL-61(补充) Approval Labeling STANDARD
2014/06/19 SUPPL-49(补充) Approval Labeling STANDARD
2014/06/09 SUPPL-60(补充) Approval Labeling STANDARD
2013/07/31 SUPPL-56(补充) Approval Labeling STANDARD
2013/06/14 SUPPL-57(补充) Approval Labeling STANDARD
2013/02/27 SUPPL-54(补充) Approval Labeling STANDARD
2011/10/07 SUPPL-52(补充) Approval Labeling UNKNOWN
2011/10/07 SUPPL-50(补充) Approval Labeling UNKNOWN
2011/10/07 SUPPL-48(补充) Approval Labeling STANDARD
2011/10/07 SUPPL-46(补充) Approval Labeling STANDARD
2009/04/23 SUPPL-47(补充) Approval Labeling 901 REQUIRED
2006/10/13 SUPPL-44(补充) Approval Labeling STANDARD
2006/01/11 SUPPL-42(补充) Approval Labeling STANDARD
2002/12/12 SUPPL-38(补充) Approval Labeling STANDARD
2000/12/20 SUPPL-35(补充) Approval Manufacturing (CMC) PRIORITY
2000/06/20 SUPPL-36(补充) Approval Manufacturing (CMC) PRIORITY
2000/06/20 SUPPL-34(补充) Approval Manufacturing (CMC) PRIORITY
2000/06/19 SUPPL-32(补充) Approval Labeling STANDARD
2000/05/16 SUPPL-29(补充) Approval Labeling STANDARD
1999/12/06 SUPPL-33(补充) Approval Manufacturing (CMC) PRIORITY
1998/09/22 SUPPL-31(补充) Approval Manufacturing (CMC) PRIORITY
1998/05/08 SUPPL-30(补充) Approval Manufacturing (CMC) PRIORITY
1996/12/02 SUPPL-28(补充) Approval Manufacturing (CMC) PRIORITY
1995/03/23 SUPPL-25(补充) Approval Manufacturing (CMC) PRIORITY
1989/03/21 SUPPL-21(补充) Approval Manufacturing (CMC) PRIORITY
1987/12/02 SUPPL-20(补充) Approval Manufacturing (CMC) PRIORITY
1986/08/11 SUPPL-18(补充) Approval Labeling
1986/05/30 SUPPL-17(补充) Approval Labeling
1986/05/30 SUPPL-15(补充) Approval Labeling
1985/12/04 SUPPL-16(补充) Approval Labeling
1983/10/28 SUPPL-14(补充) Approval Manufacturing (CMC) PRIORITY
1982/09/30 SUPPL-12(补充) Approval Manufacturing (CMC) PRIORITY
1981/12/09 SUPPL-8(补充) Approval Labeling
1981/12/09 SUPPL-5(补充) Approval Labeling
1981/11/04 SUPPL-7(补充) Approval Labeling
1980/06/16 SUPPL-4(补充) Approval Manufacturing (CMC) PRIORITY
1979/12/20 SUPPL-3(补充) Approval Manufacturing (CMC) PRIORITY
1979/12/20 SUPPL-2(补充) Approval Manufacturing (CMC) PRIORITY
1979/05/03 SUPPL-1(补充) Approval Labeling
1978/02/28 ORIG-1(原始申请) Approval Type 1 - New Molecular Entity PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
本品无治疗等效药品
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database